NCT01174043View on ClinicalTrials.gov

Pilot Study of Erlotinib for the Treatment of Patients With de Novo Acute Myeloid Leukemia

PHASE2CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

July 31, 2010

Primary Completion Date

March 31, 2012

Study Completion Date

March 31, 2012

Conditions
Leukemia, Myelomonocytic, Acute
Interventions
DRUG

Erlotinib

Erlotinib will be administered orally at 150 mg once a day, continuously. Each cycle will be 28 days and there will be no break between the cycles.

Trial Locations (1)

46202

Indiana University Melvin and Bren Simon Cancer Center, Indianapolis

Sponsors

Collaborators (1)

OSI Pharmaceuticals
All Listed Sponsors
collaborator

OSI Pharmaceuticals

INDUSTRY

lead

Indiana University

OTHER